Alizé Pharma 3 Raises €67m To Build ‘Fully Fledged’ Biotech
The Series A financing positions Alizé to take a rival to Shire’s Natpara through to clinical proof of concept over the next few years.
You may also be interested in...
A new life sciences fund, LSP 6, is one of the largest fundraisings in Europe in the sector, and will invest in around 15-to-18 pharma or medtech companies.
Private Company Edition: ARM's Q2 report shows a 38% decline in financings, but venture capital and upfront fees from deals were robust. Also, Servier raises $405m in the US, Frequency closes a $62m series C and VenatoRx accesses US government cash.
The US company is getting hold of livoletide, the French firm's late-stage ready compound for reducing hyperphagia, or insatiable hunger, in patients suffering from the rare genetic disease Prader-Willi Syndrome.